Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Ivana, Planchard, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933598/
https://www.ncbi.nlm.nih.gov/pubmed/27784815
http://dx.doi.org/10.1177/1753465816670498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933598/
https://www.ncbi.nlm.nih.gov/pubmed/27784815
http://dx.doi.org/10.1177/1753465816670498

Ejemplares similares